In 2020, Yuan et al. found that dihydroartemisinin (40 μM and 60 μM) significantly inhibited cell growth and induced ferroptosis in two human lung cancer cell lines (NCI-H23 and XWLC-05) by downregulating the level of PRIM2 after 48 h treatment. This evidence concerns the gene PRIM2 and lung carcinoma.